MedTrace Logo

A Clinical Evaluation of the ProNOVA XR Polymer Free Drug Eluting Coronary Stent System

NCT01151033 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-01-20

No results posted yet for this study

Summary

The objective of this study is the assessment of the performance, safety and efficacy of the ProNOVA XR Polymer Free Drug Eluting Stent System in the treatment of patients with de novo native coronary artery lesions.

Conditions

  • Myocardial Ischemia

Interventions

DEVICE

Drug Eluting Stent implantation

ProNOVA XR Drug Eluting Stent implantation

Sponsors & Collaborators

  • Vascular Concepts Limited

    collaborator INDUSTRY

  • KCRI

    lead OTHER

Principal Investigators

  • Dariusz Dudek, MD, PhD · Department of Haemodynamics and Angiocardiography Medical College Jagiellonian University University Hospital in Krakow

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01151033 on ClinicalTrials.gov